相似文献
1
Hepcidin agonists as therapeutic tools.
Blood. 2018 Apr 19;131(16):1790-1794. doi: 10.1182/blood-2017-11-737411. Epub 2018 Mar 9.
2
New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia.
Haematologica. 2019 Sep;104(9):1768-1781. doi: 10.3324/haematol.2018.209874. Epub 2019 Feb 21.
3
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
Blood. 2016 Jul 14;128(2):265-76. doi: 10.1182/blood-2015-10-676742. Epub 2016 May 6.
4
A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis.
Haematologica. 2015 Feb;100(2):167-77. doi: 10.3324/haematol.2014.116723. Epub 2014 Nov 25.
5
Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Haematologica. 2007 May;92(5):583-8. doi: 10.3324/haematol.10842.
6
Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
Hematol Oncol Clin North Am. 2014 Apr;28(2):387-401. doi: 10.1016/j.hoc.2013.11.004. Epub 2014 Jan 18.
7
Hepcidin biology and therapeutic applications.
Expert Rev Hematol. 2010 Apr;3(2):153-5. doi: 10.1586/ehm.10.1.
8
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
J Clin Invest. 2010 Dec;120(12):4466-77. doi: 10.1172/JCI41717. Epub 2010 Nov 22.
9
The pathophysiology and pharmacology of hepcidin.
Trends Pharmacol Sci. 2014 Mar;35(3):155-61. doi: 10.1016/j.tips.2014.01.004. Epub 2014 Feb 17.
10
Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus.
Cell Host Microbe. 2015 Jan 14;17(1):47-57. doi: 10.1016/j.chom.2014.12.001.
引用本文的文献
1
A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humans.
JCI Insight. 2025 Jun 23;10(12). doi: 10.1172/jci.insight.191813.
2
Polycythaemia vera.
Nat Rev Dis Primers. 2025 Apr 17;11(1):26. doi: 10.1038/s41572-025-00608-3.
3
Hepcidin mediates the disorder of iron homeostasis and mitochondrial function in mice under hypobaric hypoxia exposure.
Apoptosis. 2025 Apr;30(3-4):1076-1091. doi: 10.1007/s10495-025-02079-z. Epub 2025 Feb 22.
4
Cardiac injury caused by iron overload in thalassemia.
Front Pediatr. 2025 Jan 27;13:1514722. doi: 10.3389/fped.2025.1514722. eCollection 2025.
5
Hepcidin Is a Valuable Therapeutic Target for Colorectal Cancer.
Cancers (Basel). 2024 Dec 5;16(23):4068. doi: 10.3390/cancers16234068.
6
Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.
Drugs R D. 2024 Dec;24(4):539-552. doi: 10.1007/s40268-024-00497-z. Epub 2024 Nov 15.
7
Bile from the hemojuvelin-deficient mouse model of iron excess is enriched in iron and ferritin.
Metallomics. 2024 Oct 4;16(10). doi: 10.1093/mtomcs/mfae043.
8
Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives.
Front Immunol. 2024 Aug 5;15:1403458. doi: 10.3389/fimmu.2024.1403458. eCollection 2024.
9
Association of iron overload with infectious complications in liver transplant recipients: a systematic review and meta-analysis.
J Int Med Res. 2024 Mar;52(3):3000605241232920. doi: 10.1177/03000605241232920.
10
A Review of New Concepts in Iron Overload.
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):98-107.
本文引用的文献
1
What can we learn from ineffective erythropoiesis in thalassemia?
Blood Rev. 2018 Mar;32(2):130-143. doi: 10.1016/j.blre.2017.10.001. Epub 2017 Oct 3.
2
Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron.
Blood. 2017 Jul 20;130(3):245-257. doi: 10.1182/blood-2017-03-772715. Epub 2017 May 2.
3
Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia.
JCI Insight. 2017 Mar 23;2(6):e92002. doi: 10.1172/jci.insight.92002.
4
Targeting iron metabolism in drug discovery and delivery.
Nat Rev Drug Discov. 2017 Jun;16(6):400-423. doi: 10.1038/nrd.2016.248. Epub 2017 Feb 3.
5
A Red Carpet for Iron Metabolism.
Cell. 2017 Jan 26;168(3):344-361. doi: 10.1016/j.cell.2016.12.034.
6
Pharmacological Targeting of the Hepcidin/Ferroportin Axis.
Front Pharmacol. 2016 Jun 21;7:160. doi: 10.3389/fphar.2016.00160. eCollection 2016.
7
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
Blood. 2016 Jul 14;128(2):265-76. doi: 10.1182/blood-2015-10-676742. Epub 2016 May 6.
8
Haemochromatosis.
Lancet. 2016 Aug 13;388(10045):706-16. doi: 10.1016/S0140-6736(15)01315-X. Epub 2016 Mar 12.
9
New strategies to target iron metabolism for the treatment of beta thalassemia.
Ann N Y Acad Sci. 2016 Mar;1368(1):162-8. doi: 10.1111/nyas.13018. Epub 2016 Feb 25.
10
Hepcidin regulation in the anemia of inflammation.
Curr Opin Hematol. 2016 May;23(3):189-97. doi: 10.1097/MOH.0000000000000236.
Zotero 插件